Business
Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Organon is paying $75 million upfront, taking on about $9 million of Forendo debt, and up to $270 million in various development and regulatory milestones.
As the capabilities have been proven, AI is establishing a firm foothold in the key areas of R&D, drug development, clinical trials, and, to some extent, patient-facing products.
Eisai and Biogen announced positive updates on the Phase IIB 201 and open-label extension studies they are conducting on the use of lecanemab to treat early Alzheimer’s Disease.
Eric Ostertag, CEO of Poseida Therapeutics, believes the future of CAR-T programs is with allogeneic approaches and not autologous.
Cell therapy veteran Christina Coughlin is taking over the reins of the privately-held company developing natural killer immune cells to battle cancer.
Angany entered into collaboration for a series of preclinical studies that will evaluate the safety and efficacy of BP/AH-01, Angany’s lead peanut allergy biological candidate.
Investors are lighting up the season already for these biotechs, now flush with cash to spend. Here’s who snagged funding this week.
DeepCure announced the closing of its $40 million Series A financing round. The round, led by Morningside Ventures, brings the company’s total amount raised to $47 million since it was founded in 2018.
Shares of Xencor, Inc. are down nearly 6% after the company announced Novartis terminated its rights to develop vibecotamab, a CD123 x CD3 blood cancer bispecific.